Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD69 | Q07108 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.54 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.54 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.54 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30703112 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL29532484 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL29390581 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL30703110 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL3246528 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL9566107 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL14342381 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL13205049 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL9566051 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 | |
| SCHEMBL29533732 | 1.00 | CD69 (0.63) | CD69ALDH1A1THRBMAPK1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4508429-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2025-02-19 | — | — | EP | claimed |
| EP-4392780-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | Glycanostics s.r.o. (SK) | 2024-07-03 | — | — | EP | claimed |
| EP-4381291-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2024-06-12 | — | — | EP | claimed |
| WO-2023209068-A1 | PERSONALIZED ANTICANCER VACCINE COMPRISING GLYCOENGINEERED TUMOUR CELLS OR TUMOUR CELL FRAGMENTS | CARBOCALYX GMBH (DE) | 2023-11-02 | — | — | WO | claimed |
| WO-2023198337-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-10-19 | — | — | WO | claimed |
| EP-3775909-B1 | MEANS AND METHODS FOR GLYCOPROFILING OF A PROTEIN | GLYCANOSTICS S R O (SK) | 2023-05-10 | — | — | EP | claimed |
| WO-2023025927-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-02 | — | — | WO | claimed |
| WO-2023012352-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-02-09 | — | — | WO | claimed |
| EP-4705771-A1 | GLYCOPROTEIN BIOMARKERS FOR OVARIAN CANCER DIAGNOSIS | Proseek Bio Pty Ltd. (AU) | 2026-03-11 | — | — | EP | disclosed |
| EP-4508429-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024227233-A1 | GLYCOPROTEIN BIOMARKERS FOR OVARIAN CANCER DIAGNOSIS | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2024-11-07 | — | — | WO | disclosed |
| EP-4396583-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | Glycanostics s.r.o. (SK) | 2024-07-10 | — | — | EP | disclosed |
| EP-4392780-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | Glycanostics s.r.o. (SK) | 2024-07-03 | — | — | EP | disclosed |
| EP-4381291-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | Glycanostics s.r.o. (SK) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023209068-A1 | PERSONALIZED ANTICANCER VACCINE COMPRISING GLYCOENGINEERED TUMOUR CELLS OR TUMOUR CELL FRAGMENTS | CARBOCALYX GMBH (DE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023198337-A1 | MEANS AND METHODS FOR HIGH-THROUGHPUT GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023041565-A1 | USE OF LECTINS TO DETERMINE MAMMAGLOBIN-A GLYCOFORMS IN BREAST CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-23 | — | — | WO | disclosed |
| WO-2023025927-A1 | GLYCOPROTEIN BIOMARKERS FOR DIAGNOSING CANCER | GLYCANOSTICS S.R.O (SK) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023012352-A1 | STANDARD FOR GLYCOPROFILING OF PROTEINS | GLYCANOSTICS S.R.O. (SK) | 2023-02-09 | — | — | WO | disclosed |